Conventional Criteria May Underestimate Response to Treatment in Advanced Melanoma
Source: Oncology Nurse Advisor, March 2016
Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) may underestimate the treatment response in patients with advanced melanoma treated with pembrolizumab , a study published in the Journal of Clinical Oncology has shown.1
In this study, researchers sought to evaluate the atypical response patterns and the relationship between overall survival and best overall response measured using immune-related response criteria (irRC) and RECIST v1.1.
Centrally assessed irRC data was used to identify atypical responses in patients who underwent 28 or more weeks of imaging. For the study, pseudoprogression was defined as 25% or greater increase in tumor burden at week 12 (early) or any assessment after week 12 (delayed) that was not confirmed as progressive disease at the next assessment. Response was assessed centrally per irRC and RECIST v1.1.